EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Randomisierte kontrollierte Studie

Multiple Low‐Level Viraemia Suggest Hindered Liver Fibrosis Regression in Chronic Hepatitis B Patients During Antiviral Therapy

Zhengzhao Lu, Ya-Meng Sun, Shuyan Chen, Tongtong Meng, Bingqiong Wang, Jialing Zhou, Xiaoning Wu, Xinyan Zhao, Xiaojuan Ou, Yuan-Yuan Kong, Jidong Jia iD, Xinyu Zhao und 1 weitere

Journal of Viral Hepatitis · 2024

DOI: 10.1111/jvh.14012 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift Journal of Viral Hepatitis, 2024. Verfasst von Zhengzhao Lu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, …. Hauptthemen laut MEDLINE: Antiviral Agents, DNA, Viral, Hepatitis B, Chronic, Liver Cirrhosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: Capital's Funds for Health Improvement and Research (CHF 2022-1-2021), Beijing Municipal Administration of Hospitals Incubating Program (PX2022001).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Low‐level viraemia (LLV) occurs in chronic hepatitis B (CHB) patients despite antiviral treatment, which may cause failed histological regression. Our study aimed to investigate the impact of different LLV types on fibrosis regression. The prospective study enrolled CHB patients with paired liver biopsies before and after 260 weeks of entecavir treatment. Fibrosis regression was defined by the Ishak score or P‐I‐R system. Patients were grouped as the SVR (HBV DNA < 20 IU/mL persistently) or LLV (HBV DNA between 20 and 2000 IU/mL), which were further grouped as very low‐level viraemia (VLLV, HBV DNA < 50 IU/mL), occasionally LLV (OLLV, HBV DNA ≥ 50 IU/mL only once) and multiple LLV (MLLV, HBV DNA ≥ 50 IU/mL more than once). Logistic regression models were used to calculate the adjusted odds ratios (aORs) and 95% confidence intervals (CIs). The analysis included 111 CHB patients. In the SVR group ( n = 54), 39 (72.2%) patients had fibrosis regression, which was higher than the LLV (56.1%, p = 0.080). The fibrosis regression rates for VLLV (30 patients), OLLV (17 patients) and MLLV (10 patients) were 70.0%, 52.9% and 30.0%, respectively. Compared with SVR, VLLV (aOR = 0.78; 95% CI: 0.28–2.21; p = 0.644) was not associated with fibrosis regression, but patients with non‐VLLV (aOR = 0.27; 95% CI: 0.09–0.85; p = 0.025), especially with MLLV (aOR = 0.19; 95% CI: 0.04–0.97; p = 0.046) is significantly associated with hindered fibrosis regression. Our study suggests that patients with detectable serum HBV DNA levels higher than 50 IU/mL need to be monitored carefully, especially in those with more than once. Trial Registration: ClinicalTrials.gov identifiers NCT01938781 and NCT01938820

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsDNA, ViralHepatitis B, ChronicLiver CirrhosisViremiaAdultFemaleHumansMaleMiddle AgedBiopsyGuanineHepatitis B virusLiverProspective StudiesTreatment OutcomeViral Load

Stichwörter der Autor:innen

HBV DNAchronic hepatitis Bliver biopsyliver fibrosis regressionlow‐level viraemia

Substanzen

Antiviral AgentsDNA, ViralentecavirGuanine

Autor:innen und Institutionen

  • Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, National Clinical Research Center of Digestive Diseases, Beijing, Chin…
  • Clinical Epidemiology & EBM Unit, Beijing Friendship Hospital, Capital Medical University; National Clinical Research Center for Digestive Diseases, Beijing, China.

ORCID-Profile: Jidong Jia

Förderung

  • Capital's Funds for Health Improvement and Research (CHF 2022-1-2021)
  • Beijing Municipal Administration of Hospitals Incubating Program (PX2022001)

Zitieren

APA

Lu, Z., Sun, Y. M., Chen, S., Meng, T., Wang, B., Zhou, J., Wu, X., Zhao, X., Ou, X., Kong, Y. Y., Jia, J., Zhao, X., & You, H. (2024). Multiple Low‐Level Viraemia Suggest Hindered Liver Fibrosis Regression in Chronic Hepatitis B Patients During Antiviral Therapy. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.14012

Vancouver

Lu Z, Sun YM, Chen S, Meng T, Wang B, Zhou J, et al. Multiple Low‐Level Viraemia Suggest Hindered Liver Fibrosis Regression in Chronic Hepatitis B Patients During Antiviral Therapy. Journal of Viral Hepatitis. 2024. doi:10.1111/jvh.14012

BibTeX
@article{Lu2024,
  author = {Lu, Zhengzhao and Sun, Ya-Meng and Chen, Shuyan and Meng, Tongtong and Wang, Bingqiong and Zhou, Jialing and Wu, Xiaoning and Zhao, Xinyan and Ou, Xiaojuan and Kong, Yuan-Yuan and Jia, Jidong and Zhao, Xinyu and You, Hong},
  title = {Multiple Low‐Level Viraemia Suggest Hindered Liver Fibrosis Regression in Chronic Hepatitis B Patients During Antiviral Therapy},
  journal = {Journal of Viral Hepatitis},
  year = {2024},
  doi = {10.1111/jvh.14012}
}
Kostenlos starten →